Breakthrough Infections With SARS-CoV-2 Omicron Despite MRNA Vaccine Booster Dose

Contact: joanna.jia@wecistanche.com / WhatsApp: 008618081934791

The most recent SARS-CoV-2 variant of concern to emerge has been named omicron.1 Its immune evasion potential was predicted by genomic data and has been preliminarily confirmed by observations of an increased incidence of reinfections and breakthrough infections.2 This has triggered calls to intensify vaccination programs including the provision of vaccine booster doses.3

A group of German visitors who had received three doses of SARS-CoV-2 vaccines, including at least two doses of an mRNA vaccine, experienced breakthrough infections with omicron between late November and early December 2021, while in Cape Town, South Africa. The group consisted of five White women and two White men) with an average age of 27·7 years (range 25–39) and a mean body-mass index of 22·2 kg/m2 (range 17·9–29·4), with no relevant medical history. Four of the individuals were participating in clinical elective training at different hospitals in Cape Town, whereas the others were on vacation. The individuals were members of two unlinked social groups and participated in regular social life in Cape Town, in compliance with applicable COVID-19 protocols. Upon arrival during the first half of November 2021, each individual tested negative for SARS-CoV-2 by PCR and provided records of complete vaccination, including booster or third, doses administered via intramuscular injection using homologous (n=5) and heterologous (n=2) vaccination courses (appendix p 3).4

hesperidin uses about cistanche immunity

Six individuals were fully vaccinated with BNT162b2 (Comirnaty, Pfizer–BioNTech, Mainz, Germany), five of whom received a third (booster) dose of BNT162b2 in October or early November 2021. One individual had received a full dose of CX-024414 (Spikevax, Moderna, Cambridge, MA, USA) in early October 2021; this was not in line with the European Medicines Agency recommendations at that time, which suggested a half dose to boost healthy individuals.5 The seventh individual received an initial dose of ChAdOx1-S (Vaxzevria, AstraZeneca, Cambridge, UK), followed by a dose of BNT162b2 for completion of primary immunization, and a booster dose of the same vaccine. Except for the CX-024414 booster, all vaccinations were in accordance with European recommendations.4,5 The early timepoints of some individuals’ primary and booster vaccinations were due to their occupation in the medical field. Nobody reported a history of SARS-CoV-2 infection.

During a marked increase in the incidence of SARS-CoV-2 infections in the Western Cape province, these individuals observed the onset of respiratory symptoms between Nov 30 and Dec 2, 2021. SARS-CoV-2 infections were diagnosed by ISO 15189-accredited diagnostic laboratories using molecular assays approved by the national regulator. The investigation was approved by the Health Research Ethics Committees of Stellenbosch University (C21/12/004_COVID-19) and the University of Cape Town (279/2021) and all participants provided informed consent.

We obtained swabs and serum samples 2–4 days after the onset of symptoms. Further details of how samples were processed are provided in the appendix (p 2). All patients were placed in domestic isolation and used a daily symptom diary to document the course of disease during the observation period of 21 days.

Illness was classified as mild (n=4) or moderate (n=3; shortness of breath) according to National Institutes of Health COVID-19 Treatment Guidelines. Two individuals were asymptomatic by the end of the observation period (day 21). Blood oxygenation levels (SPO2) remained in the normal range (>94%) without exception and none of the patients required hospitalization. The prevalence of symptoms over time is provided in the appendix (p 4). All seven individuals were infected with omicron (PANGO lineage B.1.1.529, Nextstrain clade 21K). Viral loads ranged from 4·07 to 8·22 (mean 6·38) log10 viral RNA copies per mL of swab eluate. Anti-spike antibody levels ranged from 15 000 arbitrary units (AU) per mL to more than 40 000 AU/mL, with a mean of approximately 22000 AU/mL of serum (appendix p 3).

bioflavonoids tablets with immunity

Robust CD4 and CD8 T-cell responses to SARS-CoV-2 spike, nucleocapsid, and membrane proteins were detected in six of the participants tested after a minimum of 2 weeks after onset of symptoms (appendix p 5), at frequencies of 0·011–0·192% for CD4+ and 0·004–0·079% for CD8+ T cells.

These were the first documented breakthrough infections with the omicron variant in fully vaccinated individuals after receipt of booster vaccine doses. Some of these individuals had received heterologous vaccine doses, in line with emerging global practice. Booster doses were administered 21–37 weeks after the second vaccine doses, and breakthrough infections occurred 22–59 days thereafter. At the onset of their breakthrough infections, all individuals had high levels of viral spike protein-binding antibodies, similar to levels reported 4 weeks following second vaccine doses6 and as expected after receipt of booster vaccine doses.7

Viral RNA loads in omicron variant infections have yet to be reported. It remains unknown whether the viral loads observed in our group are different from those in unvaccinated, or differently vaccinated, individuals. During wild-type SARS-CoV-2 infection, an average viral RNA load of 5·83 log10 viral RNA copies per swab was found in samples taken up to a day after the onset of symptoms,8 with a maximum of 8·85 log10 viral RNA copies per swab. In this group of individuals, an average of 6·38 log10 viral RNA copies per mL of the eluted swab was detected, with the highest viral load (8·22 log10) detected on day 4 after the onset of symptoms. This suggests that the individuals were infectious, in keeping with the occurrence of infection clusters sparing none of the members of the two groups.

Specific T-cell responses were detected in all participants tested at least 2 weeks after symptom onset, in the range reported after vaccination,9 with additional T-cell responses to the viral nucleocapsid and membrane proteins.

The mild to moderate course of illness suggests that full vaccination followed by a booster dose still provides good protection against severe disease caused by omicron. However, we cannot exclude long-term sequelae of COVID-19. Furthermore, our findings are limited to a low number of individuals in relatively young and otherwise healthy individuals (n=7). This case series adds further evidence that, as predicted, omicron is able to evade immunity induced by mRNA vaccines in vivo. South Africa only recently introduced booster vaccinations for individuals immunized with two doses of BNT162b2, so the presence of this group from Germany presented a unique opportunity to study omicron breakthrough infections in individuals with mRNA vaccine boosters.

micronized purified flavonoid fraction 1000 mg uses about cistanche

In-vitro data suggest lower titers of neutralizing antibodies against omicron compared to other SARS-CoV-2 lineages following BNT162b2 vaccination but increased titers after a third dose,10–12 supporting calls for booster doses while the omicron variant appears to be spreading globally. Our study, however, demonstrates insufficient prevention of symptomatic infection in otherwise healthy individuals who had received three doses of COVID-19 mRNA vaccines.

These findings support the need for updated vaccines to provide better protection against symptomatic infection with omicron13 and emphasize that non-pharmaceutical measures should be maintained. Encouragingly, early data from South Africa suggest maintaining if reduced effectiveness of the BNT162b2 vaccine against hospital admission.14

Division of Hand, Plastic and Aesthetic Surgery, University Hospital, LMU Munich, Munich, Germany (CK); Division of Medical Virology, Faculty of Medicine and Health Sciences, University of Stellenbosch Tygerberg Campus, Cape Town ZA- 7505, South Africa (CKM, TM, ADS, WP); Medical Virology, National Health Laboratory Service Tygerberg, Parow, Cape Town, South Africa (MC, WP); Institute of Infectious Disease and Molecular Medicine (WAB, RK, CR) and Wellcome Centre for Infectious Diseases Research in Africa (CR); Department of Medical Biosciences, University of the Western Cape, Cape Town, South Africa (TS, MLS)

dr vita opc benefits with cistanche

Reference

1 WHO. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. Statement 26 November 2021.

2 Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with the emergence of the omicron variant in South Africa. medRxiv 2021; published online Dec 2.

3 Dolgin E. Omicron is supercharging the COVID vaccine booster debate. Dec 2, 2021.

4 European Medicines Agency. EMA and ECDC recommendations on heterologous vaccination courses against COVID-19. Dec 7, 2021.

5 covid-19 (accessed Dec 9, 2021). European Medicines Agency. Spikevax: EMA recommendation on the booster. Oct 25, 2021.

6 Grupel D, Gazit S, Schreiber L, et al. Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination. Vaccine 2021; 39: 5337–40.

7 Demonbreun AR, Sancilio A, Vaught LA, et al. Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults. medRxiv 2021; published online Nov 21.

8 Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465–69.

9 Keeton R, Richardson SI, Moyo-Gwete T, et al. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Cell Host Microbe 2021; 29: 1611–19.e5.

10 Cele S, Jackson L, Khan K, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2021; published online Dec 23.

11 Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv 2021; published online Dec 13.

12 Pfizer. Pfizer and BioNTech provide updates on the omicron variant. Press release. Dec 8, 2021.

13 Devlin H, Kollewe J. BioNTech says it could tweak the Covid vaccine in 100 days if needed. Nov 26, 2021. 2021).

14 Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med 2021; published online Dec 29.